August 30, 2018 – 2:00 – 3:00 pm ET Registries continue to be a critical part of the real-world evidence equation, but over time they have become too trialized, too burdensome, and too separated from real clinical practice. Emerging methodologies, data digitization, and cognitive technologies have set the path for drastic changes needed to address[…]
March 28, 2018 – 2 PM ET What if you could use predictive models like biomarkers to pre-emptively screen and more effectively target patients who are more likely to respond to your drug in trials and in practice? What if you could rapidly answer questions on comparative treatment outcomes and predict those most likely to[…]
February 28, 2018 – 2:00 pm – 3:00 pm ET Join Dr. Richard Gliklich, CEO of OM1, to explore the opportunities with using big data, predictive analytics and measurable outcomes to develop and implement outcomes based programs that align stakeholder incentives around benefits and costs. Discussion will include: Using standardized outcomes measurement Predicting treatment benefit,[…]
January 30, 2018 – 11 am – 12 pm ET – Register Fibrotic diseases, such as non-alcoholic steatohepatitis (NASH), are responsible for 45% of US deaths a year. With a growing occurrence and few treatment options, more research is needed to better understand natural history and progression of these diseases, treatments and outcomes. This session[…]
November 28, 2017 – Dr. Richard Gliklich As artificial intelligence and advanced analytics are increasingly lauded for uses in life sciences and healthcare, it’s becoming difficult to differentiate between the different terms, to understand what is real and what is hype, and to understand how to best leverage these technologies for advancing real-world evidence and[…]
